

TEAM EXPERIENCE – ONCOLOGY & BIOSIMILARS

Early Phase - Oncology

Molecule Name	# of studies
Alectinib 150 mg capsules	2
Dasatinib 100 mg Tablets	2
Erlotinib 150 mg Tablets	13
Ibrutinib 140 mg Capsules	13
Ibrutinib 560 mg Tablets	2
Imatinib 400 mg Tablets	2
Nintedanib 150 mg SG-Capsule	6
Osimertinib 80 mg Tablets	2
Tofacitinib 5 mg Tablets	3
Tofacitinib 11 mg ER-Tablets	12
Grand Total	57

Early Phase - Biosimilars

Molecule Name	# of studies
Adalimumab 40 mg SC InJection	1
Darbepoetin Alfa 0.75 µg/kg SC/ IV Injection	1
Darbepoetin Alfa 60/40µg SC/ IV Injection	1
Enoxaparin Na 100 mg/ml SC InJection	4
Pegfilgrastim 6 mg SC InJection	1
Repoitin Injection 10000IU/mL IV-Injection	1
Repoitin Injection 10000IU/mL SC-Injection	1
Trastuzumab 150 mg Powder IV	1
Grand Total	11

Late Phase - Oncology & Biosimilars

Molecule (Indication)	# of subject
Capecitabine (Metastatic breast/Colorectal cancer)	54
Capecitabine (Metastatic breast/Colorectal cancer)	42
Imatinib Mesylate 400 (GIST and CML)	38
Trastuzumab (Metastatic Breast Cancer)	102
Paclitaxel (Metastatic Breast Cancer)	90
Rituximab (Diffuse large B-cell lymphoma)	73
Bevacizumab (Metastatic colorectal cancer)	24
Bevacizumab (Metastatic colorectal cancer)	111
Bevacizumab (NSCLC)	650
NCE (NSCLC)	60
Lenvatinib (Thyroid Cancer)	50